VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Voyager Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.05+0.15 (+7.89%)
Close on Oct 19, 2026
- Market cap
- $124.12M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
56.9%
35M of 62M shares
Institutional holders
136
19 new, 16 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 11 sales
Net sold $297.96K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Israel A. Englander | 4,442,951 | 7.40% | 13G (passive) amendment | Jun 30, 2026 |
| EcoR1 Capital, LLC | 4,002,847 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,525,532 | 6.40% | 13G (passive) amendment | Mar 31, 2025 |
| Armistice Capital, LLC | 3,500,000 | 5.87% | 13G (passive) amendment | Mar 31, 2026 |
| Steven Boyd | 3,436,000 | 5.58% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VYGR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,172,063 | 8.39% | $18.10M | −396,318 | 0.00% |
| Millennium Management LLC | 4,442,951 | 7.21% | $15.55M | +1,014,380 | 0.01% |
| Armistice Capital, LLC | 3,436,000 | 5.58% | $12.03M | −64,000 | 0.15% |
| Vestal Point Capital, LP | 2,625,000 | 4.26% | $9.19M | −377,936 | 0.21% |
| Vanguard Capital Management LLC | 2,345,674 | 3.81% | $8.21M | +62,421 | 0.00% |
| Geode Capital Management, LLC | 1,330,492 | 2.16% | $4.66M | +280,514 | 0.00% |
| Opaleye Management Inc. | 1,185,000 | 1.92% | $4.15M | +35,000 | 0.38% |
| State Street Corp | 1,076,422 | 1.75% | $3.77M | +128,196 | 0.00% |
| Two Sigma Investments, LP | 948,517 | 1.54% | $3.32M | +332,857 | 0.00% |
| Dimensional Fund Advisors LP | 838,184 | 1.36% | $2.93M | −37,384 | 0.00% |
| Vanguard Portfolio Management LLC | 810,091 | 1.31% | $2.84M | +84,322 | 0.00% |
| Citadel Advisors LLC | 784,067 | 1.27% | $2.74M | +419,403 | 0.00% |
| Morgan Stanley | 697,334 | 1.13% | $2.44M | +15,623 | 0.00% |
| Erste Asset Management GmbH | 638,900 | 1.04% | $2.29M | −456,241 | 0.02% |
| Renaissance Technologies LLC | 495,236 | 0.80% | $1.73M | −82,788 | 0.00% |
| Acadian Asset Management LLC | 428,670 | 0.70% | $1.50K | +179,799 | 0.00% |
| Sphera Funds Management Ltd. | 427,554 | 0.69% | $1.50M | −42,207 | 0.20% |
| Diadema Partners LP | 413,642 | 0.67% | $1.45M | −10,000 | 0.18% |
| Northern Trust Corp | 411,803 | 0.67% | $1.44M | +26,960 | 0.00% |
| Aqr Capital Management LLC | 356,109 | 0.58% | $1.25M | +123,428 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 136 | 35M | 56.9% | 19 / 58 | 34 / 16 | 4M | 3M |
| Q1 2026 | 135 | 34M | 54.4% | 28 / 46 | 36 / 17 | 10M | 7M |
| Q4 2025 | 125 | 34M | 54.8% | 19 / 30 | 46 / 8 | 6M | 2M |
| Q3 2025 | 117 | 30M | 49.4% | 23 / 33 | 38 / 18 | 3M | 6M |
| Q2 2025 | 112 | 33M | 54.3% | 14 / 33 | 36 / 18 | 3M | 5M |
| Q1 2025 | 116 | 35M | 56.4% | 13 / 35 | 41 / 27 | 2M | 2M |
| Q4 2024 | 132 | 35M | 56.2% | 25 / 44 | 37 / 18 | 3M | 3M |
| Q3 2024 | 128 | 35M | 57.5% | 20 / 38 | 36 / 18 | 7M | 5M |
| Q2 2024 | 127 | 38M | 62.3% | 23 / 41 | 42 / 28 | 5M | 3M |
| Q1 2024 | 132 | 36M | 59.2% | 33 / 57 | 29 / 7 | 10M | 1M |
| Q4 2023 | 107 | 28M | 44.8% | 20 / 33 | 30 / 23 | 3M | 2M |
| Q3 2023 | 110 | 27M | 44.2% | 21 / 35 | 33 / 17 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VYGR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,671,885 | 2.71% | $5.85M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,376,036 | 2.23% | $4.82M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 613,128 | 1.00% | $2.15M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 570,437 | 0.93% | $1.73M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 489,996 | 0.80% | $1.71M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 457,063 | 0.74% | $1.38M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 348,405 | 0.57% | $1.22M | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 240,078 | 0.39% | $929.10K | 0.01% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 225,281 | 0.37% | $871.84K | 0.02% | May 29, 2026 |
| U.S. Small Cap Portfolio | 220,820 | 0.36% | $669.08K | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 220,367 | 0.36% | $852.82K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 176,641 | 0.29% | $618.24K | 0.04% | Jun 30, 2026 |
| Bridge Builder Tax Managed Small/Mid Cap Fund | 157,086 | 0.25% | $549.80K | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 138,411 | 0.22% | $484.44K | 0.01% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 128,451 | 0.21% | $389.21K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alfred Sandrock | President and CEO, Director | 472,549 | 0.77% | Apr 3, 2026 |
| Amy Quinlan | Principal Accounting Officer | 36,749 | 0.06% | May 18, 2026 |
| Gregory L. Shiferman | SVP and General Counsel | 50,000 | 0.08% | Apr 3, 2026 |
| Nathan D. Jorgensen | Chief Financial Officer | 151,416 | 0.25% | Feb 26, 2026 |
| Robin Swartz | COO & CBO | 199,738 | 0.32% | Feb 26, 2026 |
| Todd Alfred Carter | Chief Scientific Officer | 145,718 | 0.24% | Feb 26, 2026 |
| Toby Ferguson | Chief Medical Officer | 183,914 | 0.30% | Feb 10, 2026 |
| Sandell Jacquelyn Fahey | Chief Legal Officer | 123,143 | 0.20% | Feb 24, 2025 |
| Catherine J. Mackey | Director | – | – | Jun 11, 2026 |
| Nancy Vitale | Director | – | – | Jun 11, 2026 |
| James A. Geraghty | Director | 76,588 | 0.12% | Jun 11, 2026 |
| George A. Scangos | Director | – | – | Jun 11, 2026 |
| Michael J. Higgins | Director | 31,314 | 0.05% | Jun 11, 2026 |
| Steven Hyman | Director | – | – | Jun 11, 2026 |
| Glenn Pierce | Director | 21,788 | 0.04% | Jun 11, 2026 |
| Grace Colon | Director | – | – | Jun 11, 2026 |
| Jude Onyia | Director | 2,910 | 0.00% | Jun 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alfred Sandrock President and CEO, Director | Apr 2, 2026 | Sale(10b5-1 plan) | −11,511 | $3.87 | $44.55K | 472,549 |
| Gregory L. Shiferman SVP and General Counsel | Apr 1, 2026 | Award | +50,000 | – | – | 50,000 |
| Nathan D. Jorgensen Chief Financial Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −4,668 | $3.77 | $17.60K | 151,416 |
| Robin Swartz COO & CBO | Feb 24, 2026 | Sale(10b5-1 plan) | −6,458 | $3.77 | $24.35K | 199,738 |
| Todd Alfred Carter Chief Scientific Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −4,174 | $3.76 | $15.69K | 145,718 |
| Alfred Sandrock President and CEO, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −14,197 | $3.79 | $53.81K | 484,060 |
| Todd Alfred Carter Chief Scientific Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −3,301 | $3.44 | $11.36K | 149,892 |
| Alfred Sandrock President and CEO, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −11,732 | $3.41 | $40.01K | 498,257 |
| Robin Swartz COO & CBO | Feb 18, 2026 | Sale(10b5-1 plan) | −3,882 | $3.44 | $13.35K | 206,196 |
| Alfred Sandrock President and CEO, Director | Feb 10, 2026 | Sale | −12,192 | $3.78 | $46.09K | 509,989 |
| Robin Swartz COO & CBO | Feb 10, 2026 | Sale | −4,569 | $3.85 | $17.59K | 210,078 |
| Todd Alfred Carter Chief Scientific Officer | Feb 10, 2026 | Sale | −3,525 | $3.85 | $13.57K | 153,193 |
| Robin Swartz COO & CBO | Feb 6, 2026 | Award | +45,000 | – | – | 214,647 |
| Alfred Sandrock President and CEO, Director | Feb 6, 2026 | Award | +86,250 | – | – | 522,181 |
| Toby Ferguson Chief Medical Officer | Feb 6, 2026 | Award | +45,000 | – | – | 183,914 |
| Todd Alfred Carter Chief Scientific Officer | Feb 6, 2026 | Award | +33,000 | – | – | 156,718 |
| Nathan D. Jorgensen Chief Financial Officer | Feb 6, 2026 | Award | +32,250 | – | – | 156,084 |
| Nathan D. Jorgensen Chief Financial Officer | Oct 3, 2025 | Sale(10b5-1 plan) | −7,666 | $4.78 | $36.64K | 123,834 |
| Toby Ferguson Chief Medical Officer | Aug 18, 2025 | Sale | −19,000 | $3.73 | $70.87K | 138,914 |
| Alfred Sandrock President and CEO, Director | Apr 2, 2025 | Sale | −10,885 | $3.43 | $37.34K | 430,931 |
| Toby Ferguson Chief Medical Officer | Apr 2, 2025 | Sale | −10,086 | $3.43 | $34.59K | 157,914 |
| Nathan D. Jorgensen Chief Financial Officer | Feb 21, 2025 | Award | +51,500 | – | – | 131,500 |
| Toby Ferguson Chief Medical Officer | Feb 21, 2025 | Award | +63,000 | – | – | 168,000 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Feb 21, 2025 | Award | +41,500 | – | – | 123,143 |
| Alfred Sandrock President and CEO, Director | Feb 21, 2025 | Award | +145,000 | – | – | 441,816 |
| Robin Swartz COO & CBO | Feb 21, 2025 | Award | +71,250 | – | – | 169,647 |
| Todd Alfred Carter Chief Scientific Officer | Feb 21, 2025 | Award | +46,000 | – | – | 123,718 |
| Alfred Sandrock President and CEO, Director | Feb 20, 2025 | Sale | −11,702 | $4.24 | $49.62K | 296,816 |
| Robin Swartz COO & CBO | Feb 20, 2025 | Sale | −3,894 | $4.25 | $16.55K | 98,397 |
| Todd Alfred Carter Chief Scientific Officer | Feb 20, 2025 | Sale | −3,305 | $4.26 | $14.08K | 77,718 |
| Alfred Sandrock President & CEO | Feb 11, 2025 | Sale | −16,644 | $4.45 | $74.07K | 308,518 |
| Todd Alfred Carter Chief Scientific Officer | Feb 11, 2025 | Sale | −5,413 | $4.45 | $24.09K | 81,023 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Feb 11, 2025 | Sale | −4,358 | $4.45 | $19.39K | 81,643 |
| Robin Swartz COO & CBO | Feb 11, 2025 | Sale | −6,950 | $4.45 | $30.93K | 102,291 |
| Robin Swartz COO & CBO | Jan 14, 2025 | Sale | −3,087 | $5.09 | $15.71K | 109,241 |
| Todd Alfred Carter Chief Scientific Officer | Jan 14, 2025 | Sale | −1,191 | $5.13 | $6.11K | 86,436 |
| Robin Swartz COO&CBO | Dec 23, 2024 | Sale | −6,500 | $5.65 | $36.73K | 112,328 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Oct 2, 2024 | Sale | −5,999 | $5.82 | $34.91K | 86,001 |
| Nathan D. Jorgensen Chief Financial Officer | Oct 1, 2024 | Award | +80,000 | – | – | 80,000 |
| Alfred Sandrock President and CEO, Director | Apr 2, 2024 | Sale | −12,115 | $9.86 | $119.45K | 322,839 |
| Robin Swartz Chief Operating Officer | Apr 2, 2024 | Sale | −1,357 | $9.88 | $13.41K | 117,004 |
| Toby Ferguson Chief Medical Officer | Apr 1, 2024 | Award | +105,000 | – | – | 105,000 |
| Peter P. Pfreundschuh Chief Financial Officer | Feb 21, 2024 | Sale | −3,764 | $7.46 | $28.08K | 175,669 |
| Todd Alfred Carter Chief Scientific Officer | Feb 21, 2024 | Sale | −3,365 | $7.47 | $25.14K | 87,627 |
| Robin Swartz Chief Operating Officer | Feb 21, 2024 | Sale | −3,966 | $7.45 | $29.55K | 118,361 |
| Alfred Sandrock President and CEO, Director | Feb 21, 2024 | Sale | −13,033 | $7.46 | $97.23K | 334,954 |
| Todd Alfred Carter Chief Scientific Officer | Feb 20, 2024 | Sale | −602 | $7.68 | $4.62K | 90,992 |
| Peter P. Pfreundschuh Chief Financial Officer | Feb 9, 2024 | Award | +30,000 | – | – | 179,433 |
| Alfred Sandrock President and CEO, Director | Feb 9, 2024 | Award | +130,000 | – | – | 347,987 |
| Todd Alfred Carter Chief Scientific Officer | Feb 9, 2024 | Award | +38,500 | – | – | 91,594 |
| Robin Swartz Chief Operating Officer | Feb 9, 2024 | Award | +50,000 | – | – | 122,327 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Feb 9, 2024 | Award | +31,000 | – | – | 92,000 |
| Robin Swartz Chief Operating Officer | Jan 17, 2024 | Sale | −2,543 | $7.15 | $18.18K | 72,327 |
| Todd Alfred Carter Chief Scientific Officer | Jan 17, 2024 | Sale | −1,266 | $7.18 | $9.09K | 53,094 |
| Peter P. Pfreundschuh Chief Financial Officer | Oct 3, 2023 | Sale | −13,567 | $6.99 | $94.83K | 149,433 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Oct 1, 2023 | Award | +61,000 | – | – | 61,000 |
| Todd Alfred Carter Chief Scientific Officer | Sep 15, 2023 | Option exercise | +5,000 | $2.85 | $14.25K | 64,860 |
| Todd Alfred Carter Chief Scientific Officer | Sep 15, 2023 | Sale(10b5-1 plan) | −10,500 | $8.16 | $85.68K | 54,360 |
| Todd Alfred Carter Chief Scientific Officer | Jul 6, 2023 | Sale(10b5-1 plan) | −5,500 | $10.80 | $59.40K | 59,860 |
| Todd Alfred Carter Chief Scientific Officer | Jun 30, 2023 | Sale(10b5-1 plan) | −5,000 | $11.41 | $57.05K | 65,360 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nathan D. Jorgensen Former Officer | May 15, 2026 | 9,406 | $39.88K | May 15, 2026 | Option Granted - 02/06/2026 |
| Nathan D. Jorgensen Former Officer | May 15, 2026 | 25,000 | $96.94K | May 15, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Apr 2, 2026 | 11,511 | $44.60K | Apr 2, 2026 | Restricted Stock Vesting |
| Nathan D. Jorgensen Officer | Feb 24, 2026 | 4,668 | $17.59K | Feb 24, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Feb 24, 2026 | 14,197 | $53.85K | Feb 24, 2026 | Restricted Stock Vesting |
| Robin Swartz Officer | Feb 24, 2026 | 6,458 | $24.34K | Feb 24, 2026 | Restricted Stock Vesting |
| Todd Alfred Carter Officer | Feb 24, 2026 | 4,174 | $15.71K | Feb 24, 2026 | Restricted Stock Vesting |
| Robin Swartz Officer | Feb 18, 2026 | 3,882 | $13.35K | Feb 18, 2026 | Restricted Stock Vesting |
| Todd Alfred Carter Officer | Feb 18, 2026 | 3,301 | $11.35K | Feb 18, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Feb 18, 2026 | 11,732 | $40.04K | Feb 18, 2026 | Restricted Stock Vesting |
| Robin Swartz Officer | Feb 10, 2026 | 4,569 | $17.60K | Feb 10, 2026 | Restricted Stock Vesting |
| Todd Alfred Carter Officer | Feb 10, 2026 | 3,525 | $13.55K | Feb 10, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Feb 10, 2026 | 12,192 | $46.09K | Feb 10, 2026 | Restricted Stock Vesting |
| Nathan D. Jorgensen Officer | Oct 3, 2025 | 7,666 | $36.63K | Oct 3, 2025 | Restricted Stock Vesting |
| Sandell Jacquelyn Fahey Officer | Oct 3, 2025 | 5,843 | $27.94K | Oct 3, 2025 | Restricted Stock Vesting |